Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas
Jenny Kreahling(Moffitt Cancer Center), Soner Altiok(Moffitt Cancer Center)
Cited by 89
Related Papers
PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A
|Genes & Development|1997|380
MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
|Molecular Cancer Therapeutics|2011|122